Summary & Overview
HCPCS J0224: Injection, lumasiran, 0.5 mg
HCPCS Level II code J0224 denotes the injectable drug lumasiran in 0.5 mg units and is used to bill for the medication component of patient care when lumasiran is administered. Lumasiran is a targeted RNA therapy with specific clinical indications, and accurate coding is essential for drug inventory, payer adjudication, and national monitoring of specialty pharmaceutical utilization. This code matters nationally as specialty injectables represent a growing share of drug spend and require precise HCPCS reporting for coverage determinations and Medicare program oversight. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service where lumasiran is administered, and which payers are included in the coverage review. The publication also outlines what to expect in related benchmark and policy sections, including coverage and utilization benchmarks, coding guidance updates, and the clinical setting for administration. Data not available in the input for associated taxonomies, ICD-10 diagnoses, or payer-specific policy details are noted where appropriate.
Billing Code Overview
HCPCS Level II code J0224 represents the medication lumasiran supplied for injection, with a billing unit of 0.5 mg per code descriptor. This HCPCS entry is used to capture the drug product when lumasiran is administered as an injectable therapy.
Service Type: Drug administration (injectable medication)
Typical Site of Service: Outpatient infusion/ambulatory infusion center, physician office, or hospital outpatient department
Data not available in the input for associated taxonomies, ICD-10 diagnoses, or related procedure codes.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual diagnosed with primary hyperoxaluria type 1 (PH1) who is receiving therapy with lumasiran. The medication J0224 represents injectable lumasiran dosed in 0.5 mg increments. A common scenario: the patient presents to an infusion clinic, pediatric specialty clinic, or outpatient ambulatory surgical center for administration of the intramuscular or subcutaneous injection per manufacturer dosing schedule. Pre-visit workflow includes verification of diagnosis, medication authorization, weight-based dose calculation, allergies review, medication reconciliation, and informed consent for therapy. On the day of service nursing performs medication preparation, verifies the correct product and lot, documents vial/lot/JW wastage if applicable, and administers the injection. Post-administration monitoring for immediate adverse reactions (vital signs observation, site inspection) occurs for the recommended period prior to discharge. Documentation includes medication name lumasiran, billed code J0224 with quantity reflecting total 0.5 mg units administered, relevant modifier(s) for payer billing, injection site, route, lot numbers, and any unused drug waste dispositions. Typical sites of service are outpatient infusion centers, ambulatory clinics, and specialty pharmacy–coordinated clinic injection visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|